| Bioactivity | PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expression and decrease PCSK9 protein expression in hepG2 cells. PCSK9-IN-29 can reduce the levels of serum LDL-C, TC, and liver enzyme ALT in crab eating macaques fed a high-fat diet, lower body weight and fat, and increase bone mineral content. PCSK9-IN-29 can be used for research on non-alcoholic fatty liver disease and obesity[1]. |
| CAS | 1233353-86-0 |
| Formula | C26H26FNO6S |
| Molar Mass | 499.55 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liu, jing wen, et al. 治疗 NASH、NAFLD 和肥胖症的化合物、组合物和方法. China, CN115279755A. 2022-11-01. |
PCSK9-IN-29
CAS: 1233353-86-0 F: C26H26FNO6S W: 499.55
PCSK9-IN-29 is a lipid-lowering agent. PCSK9-IN-29 can increase low-density lipoprotein receptor (LDLR) protein expressi
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.